Article citationsMore>>

Fabian, M.A., Biggs III, W.H., Treiber, D.K., Atteridge, C.E., Azimioara, M.D., Benedetti,M.G., Carter, T.A., Ciceri, P., Edeen, P.T., Floyd, M., Ford, M., Galvin, J.M., Gerlach, M., Gortzfeld, J.L., Herrgard, R.M., Insko, S., Insko, M.A., Lai, A.G., Lelias, J.M., Mehta, S.A., Milanov, Z.V., Velasco, A.M., Wodicka, L.M., Patel, H.K., Zarrinkar, P.P. and Lockhart, D.J. (2005) A Small Molecule—Kinase Interaction Map for Clinical Kinase Inhibitors. Nature Biotechnology, 23, 329-336.
http://dx.doi.org/10.1038/nbt1068

has been cited by the following article:

• TITLE: Molecular Docking Studies of Myricetin and Its Analogues against Human PDK-1 Kinase as Candidate Drugs for Cancer

  AUTHORS: Shalini Singh, Pradeep Srivastava

  KEYWORDS: Myricetin, PDK-1, ADMET, Docking, Analogues

  JOURNAL NAME: Computational Molecular Bioscience, Vol.5 No.2, June 30, 2015

  ABSTRACT: Phosphoinositide-dependent protein kinase-1 (PDK1), the class of serine threonine kinase, is a master regulator of the AGC family of kinases. It is a main component of the PI3K pathway. As it is reported that this pathway is most commonly, and this pathway is the most commonly deregulated among many cancers. So designing a selective inhibitor of PDK1 may have the efficacy as an anticancer agent. Herein, we describe our work focused on the structure based on screening of 95% similar analogues of Myricetin deposited in PubChem database as earlier studies have been suggested that myricetin acts as an anti cancer agent. Further molecular docking as well as the in silico ADMET studies are incorporated on these compounds to evaluate the binding and pharmacokinetic properties of these compounds. Due to low oral bioavailability, clinical use of myricetin is limited. Therefore this study is an attempt towards screening of structurally similar better compounds as compare with myricetin which can act as better inhibitor against PDK-1.